Yousif Capital Management LLC grew its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 8.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,653 shares of the medical instruments supplier's stock after purchasing an additional 4,950 shares during the quarter. Yousif Capital Management LLC's holdings in Becton, Dickinson and Company were worth $14,809,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also bought and sold shares of the business. Bank of Jackson Hole Trust purchased a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at approximately $25,000. Sierra Ocean LLC purchased a new position in shares of Becton, Dickinson and Company in the 4th quarter worth approximately $29,000. REAP Financial Group LLC lifted its holdings in shares of Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 55 shares during the last quarter. Picton Mahoney Asset Management grew its stake in shares of Becton, Dickinson and Company by 61.4% during the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after acquiring an additional 54 shares during the last quarter. Finally, Nexus Investment Management ULC acquired a new stake in shares of Becton, Dickinson and Company during the first quarter worth $34,000. 86.97% of the stock is owned by institutional investors.
Becton, Dickinson and Company Trading Down 1.4%
NYSE BDX traded down $2.40 during trading hours on Friday, hitting $172.06. 2,276,369 shares of the company's stock were exchanged, compared to its average volume of 1,975,669. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. The firm has a market capitalization of $49.31 billion, a P/E ratio of 28.58, a price-to-earnings-growth ratio of 1.63 and a beta of 0.25. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The business's 50 day moving average is $183.03 and its 200-day moving average is $213.07.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. The business had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. During the same quarter last year, the firm earned $3.17 earnings per share. The company's revenue for the quarter was up 4.5% compared to the same quarter last year. As a group, analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.
Becton, Dickinson and Company Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 9th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.42%. The ex-dividend date is Monday, June 9th. Becton, Dickinson and Company's payout ratio is 79.39%.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on the company. Citigroup downgraded Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and reduced their target price for the stock from $217.00 to $185.00 in a research note on Thursday, May 22nd. Piper Sandler lowered Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and lowered their price target for the stock from $260.00 to $185.00 in a research report on Friday, May 2nd. Stifel Nicolaus cut their price objective on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Wells Fargo & Company lowered shares of Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a report on Thursday, May 1st. Finally, The Goldman Sachs Group cut shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price objective on the stock. in a report on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $219.22.
Check Out Our Latest Analysis on Becton, Dickinson and Company
Insider Transactions at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the sale, the executive vice president now directly owns 4,575 shares of the company's stock, valued at approximately $783,194.25. This represents a 20.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Richard Byrd sold 459 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $230.00, for a total transaction of $105,570.00. Following the sale, the executive vice president now directly owns 6,952 shares in the company, valued at approximately $1,598,960. This trade represents a 6.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,104 shares of company stock worth $399,675. Insiders own 0.36% of the company's stock.
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
See Also
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
